Rockwell Medical (FRA:RWM) 10-Year RORE % : -13.29% (As of Mar. 2026)


FRA:RWM Rockwell Medical Inc FRA:RWM
30 GF Score
Price €5.25
GF Value €0.90
Valuation Significantly Overvalued
! 3 Warning Signs
View Full Analysis

What is Rockwell Medical 10-Year RORE %?

Rockwell Medical FRA:RWM 30 10-Year RORE % is -13.29 as of Mar. 2026. GuruFocus rates FRA:RWM with a GF Score™ of 30/100 and a GF Value™ of €0.90 (Significantly Overvalued). The stock has 3 warning signs investors should review. Among 670 Drug Manufacturers companies, Rockwell Medical ranks worse than 79.4% on this metric.

Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments. Rockwell Medical's 10-Year RORE % for the quarter that ended in Mar. 2026 was -13.29%.

The industry rank for Rockwell Medical's 10-Year RORE % or its related term are showing as below:

FRA:RWM's 10-Year RORE % is ranked worse than
79.4% of 670 companies
in the Drug Manufacturers industry
Industry Median: 6.405 vs FRA:RWM: -13.29

Rockwell Medical  (FRA:RWM) 10-Year RORE % Explanation

Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.

There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 10-year period is chosen.

Be Aware

Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.


Rockwell Medical 10-Year RORE % Related Terms


Rockwell Medical 10-Year RORE % Historical Data

* Premium members only.

The historical data trend for Rockwell Medical's 10-Year RORE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Rockwell Medical 10-Year RORE % Chart

Rockwell Medical Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
10-Year RORE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -27.05 -24.31 -11.06 -8.84 -13.06

Rockwell Medical Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
10-Year RORE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -9.96 -11.81 -13.01 -13.06 -13.29

FRA:RWM vs CPHI, TXMD, MRMD: 10-Year RORE % Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Rockwell Medical's 10-Year RORE %, along with its competitors' market caps and 10-Year RORE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Rockwell Medical 10-Year RORE % vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Rockwell Medical's 10-Year RORE % distribution charts can be found below:

* The bar in red indicates where Rockwell Medical's 10-Year RORE % falls into.


FRA:RWM
30GF Score
Rockwell Medical Inc FRA:RWM
10-Year RORE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Rockwell Medical 10-Year RORE % Calculation

Rockwell Medical's 10-Year RORE % for the quarter that ended in Mar. 2026 is calculated as:

10-Year RORE %=( Most Recent EPS (Diluted)- First Period EPS (Diluted) )/( Cumulative EPS (Diluted) for 10-year -Cumulative Dividends per Share for 10-year )
=( -1.29--39.274 )/( -285.793-0 )
=37.984/-285.793
=-13.29 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of 10-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Mar. 2026 and 10-year before.

Frequently Asked Questions Learn more about 10-Year RORE % →
What does a 10-Year RORE % of -13.29 mean?
Rockwell Medical (FRA:RWM) has a 10-Year RORE % of -13.29 as of Mar. 2026. 10-Year RORE % shows how much a company earns by reinvesting its retained earnings in 10-year. View historical data on Rockwell Medical and its competitors. According to the industry distribution chart, Rockwell Medical ranks #532 out of 670 companies in the Drug Manufacturers industry, placing it in the top 79.4%.
Is Rockwell Medical's 10-Year RORE % too high?
Rockwell Medical's current 10-Year RORE % is -13.29. Based on the distribution chart, Rockwell Medical ranks #532 out of 670 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Rockwell Medical has a GF Score™ of 30/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Rockwell Medical's 10-Year RORE % compare to CPHI and TXMD?
According to the Drug Manufacturers industry distribution chart, Rockwell Medical ranks #532 out of 670 companies for 10-Year RORE %. This places Rockwell Medical in the lower half of its industry. The industry median 10-Year RORE % is 6.41. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 10-Year RORE % for a Drug Manufacturers company?
The median 10-Year RORE % among Drug Manufacturers companies is 6.41, based on 670 companies in the industry. Companies in the top quartile (top 25%) have a 10-Year RORE % significantly above this median, while those in the bottom quartile fall well below. However, 10-Year RORE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 10-Year RORE % mean?
A high 10-Year RORE % can signal that a stock is expensive relative to its fundamentals. 10-Year RORE % shows how much a company earns by reinvesting its retained earnings in 10-year. View historical data on Rockwell Medical and its competitors. For the Drug Manufacturers industry, the median 10-Year RORE % is 6.41 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Rockwell Medical's current 10-Year RORE % is -13.29. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Rockwell Medical stock overvalued right now?
Based on GuruFocus' analysis, Rockwell Medical (FRA:RWM) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.90, compared to a current price of €5.25 — trading 483.3% above its estimated fair value. The current 10-Year RORE % is -13.29. Rockwell Medical's overall GF Score™ is 30/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 10-Year RORE % calculated?
10-Year RORE % is calculated from a company's financial statements. For Rockwell Medical (FRA:RWM), the current 10-Year RORE % is -13.29 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Rockwell Medical (FRA:RWM) Overvalued in 2026?

Based on GuruFocus' analysis, Rockwell Medical stock appears to be overvalued. The current stock price of €5.25 is trading 483.3% above its estimated GF Value™ of €0.90. GuruFocus considers Rockwell Medical to be Significantly Overvalued.

Key valuation signals for FRA:RWM:

  • 10-Year RORE %: -13.29
  • GF Value™: €0.90 vs. price of €5.25 (483.3% above fair value)
  • GF Score™: 30/100 with 3 warning signs

No single metric tells the full story. See the FRA:RWM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Rockwell Medical Business Description

Other Exchanges RMTI:USA
Address 30142 South Wixom Road, Wixom, MI, USA, 48393
Rockwell Medical Inc is a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products for dialysis providers. It is a supplier of liquid bicarbonate concentrates, acid, and dry bicarbonate concentrates for dialysis patients in the United States. The company's products include CitraPure citric acid concentrate, RenalPure liquid acid concentrate, and SteriLyte bicarbonate concentrate, among others. The company delivers the majority of its hemodialysis concentrates products and mixers to dialysis clinics throughout the United States and internationally, utilizing its own delivery trucks and third-party carriers.
30GF Score

Get the complete analysis for FRA:RWM

10-Year RORE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€5.25
Price
€0.90
GF Value